Relationship between inflammation and metabolic syndrome following treatment with paliperidone for schizophrenia.
OBJECTIVE
Metabolic syndrome and antipsychotic medications are associated with inflammation. This study investigated the relationship between inflammation and metabolic syndrome in patients with schizophrenia. It also examined the effects of paliperidone extended release (ER) treatment on metabolic parameters.


METHODS
Data were analyzed from schizophrenic patients who participated in a multi-center, open-label, non-comparative clinical trial. Anthropomorphic measurements (i.e., weight, waist circumference, and blood pressure) were assessed along with fasting laboratory values, including white blood cell (WBC) count, glucose, high-density lipoprotein, and triglycerides.


RESULTS
Among the 225 patients at baseline, the group with the highest WBC count displayed a 5.9-fold risk for metabolic syndrome compared with that of the lowest group. An increase of 10(3)WBCs/μL was associated with a 1.4-fold increased risk for metabolic syndrome. After 24weeks of treatment with paliperidone ER, significant increases were observed in waist circumference and body weight. Changes in WBC count were positively correlated with changes in waist circumference.


CONCLUSIONS
Schizophrenic patients with high levels of inflammation should be carefully monitored for metabolic syndrome. Moreover, strategies to reduce inflammation and obesity may prevent metabolic syndrome in patients with schizophrenia who take atypical antipsychotic medication.
Department of Psychiatry, Soonchunhyang University Bucheon Hospital, Bucheon, Republic of Korea.
Kyoung-Sae
KS
Na
Won-Hyoung
WH
Kim
Han-Yong
HY
Jung
Seong Gon
SG
Ryu
Kyung Joon
KJ
Min
Ki-Chang
KC
Park
Yong-Sik
YS
Kim
Jin-Sang
JS
Yoon
Yong Min
YM
Ahn
Chul-Eung
CE
Kim
D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D003692:Delayed-Action Preparations / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007249:Inflammation / Q000139:chemically induced / Q000150:complications / Q000378:metabolism*; D007555:Isoxazoles / Q000008:administration & dosage / Q000009:adverse effects*; D007958:Leukocyte Count / Q000706:statistics & numerical data; D008297:Male; D024821:Metabolic Syndrome / Q000139:chemically induced / Q000150:complications / Q000378:metabolism*; D008875:Middle Aged; D000068882:Paliperidone Palmitate; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects*; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*
D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; D007555:Isoxazoles; D011743:Pyrimidines; D000068882:Paliperidone Palmitate